Contineum Therapeutics Files 8-K for Bylaws and Financials
Ticker: CTNM · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1855175
| Field | Detail |
|---|---|
| Company | Contineum Therapeutics, Inc. (CTNM) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, financials, filing
TL;DR
Contineum Therapeutics filed an 8-K for corporate updates and financials.
AI Summary
Contineum Therapeutics, Inc. filed an 8-K on April 9, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, formerly known as Pipeline Therapeutics, Inc. until April 5, 2021, is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing indicates routine corporate updates and financial reporting, providing transparency on the company's administrative and financial status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for corporate and financial updates, not indicating any immediate material changes or risks.
Key Numbers
- 001-42001 — SEC File Number (Identifies the company's filing with the SEC)
- 27-1467257 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Contineum Therapeutics, Inc. (company) — Registrant
- Pipeline Therapeutics, Inc. (company) — Former company name
- April 9, 2024 (date) — Date of report
- April 5, 2021 (date) — Date of name change
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What specific amendments were made to Contineum Therapeutics' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the excerpt.
What is the primary business of Contineum Therapeutics?
Contineum Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
When did Contineum Therapeutics change its name from Pipeline Therapeutics, Inc.?
The company changed its name on April 5, 2021.
Where are Contineum Therapeutics' principal executive offices located?
The principal executive offices are located at 10578 Science Center Drive, Suite 200, San Diego, California, 92121.
What is the fiscal year end for Contineum Therapeutics?
The fiscal year end for Contineum Therapeutics is December 31.
Filing Stats: 1,085 words · 4 min read · ~4 pages · Grade level 14.6 · Accepted 2024-04-09 16:49:49
Key Financial Figures
- $0.001 — tered Class A Common Stock, par value $0.001 per share CTNM The Nasdaq Global Ma
Filing Documents
- d811673d8k.htm (8-K) — 22KB
- d811673dex31.htm (EX-3.1) — 40KB
- d811673dex32.htm (EX-3.2) — 162KB
- 0001193125-24-090917.txt ( ) — 225KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 9, 2024 Contineum Therapeutics, Inc. By: /s/ Carmine Stengone Carmine Stengone Chief Executive Officer and President Principal Executive Officer